TIMP-2 Modulates VEGFR-2 Phosphorylation and Enhances Phosphodiesterase Activity in Endothelial Cells

Overview

Journal Lab Invest

Specialty Pathology

Date 2010 Jan 20

PMID 20084057

Citations 23

Authors

Seo-Jin Lee

Patricia S Tsang

Tere M Diaz

Bei-yang Wei

William George Stetler-Stevenson

Affiliations

Soon will be listed here.

Abstract

In this study, we examine the effects of tissue inhibitor of metalloproteinases-2 (TIMP-2) on the phosphorylation status of specific phosphotyrosine residues on the vascular endothelial cell growth factor receptor-2 (VEGFR-2) cytoplasmic tail and examine the effects on associated downstream signaling pathways. To focus on metalloproteinase-independent mechanisms, we used the TIMP-2 analog known as Ala+TIMP-2 that is deficient in matrix metalloproteinase-inhibitory activity. Our experiments are designed to compare the effects of VEGF-A stimulation with or without Ala+TIMP-2 pretreatment, as well as basal responses in human microvascular endothelial cells. Our results show that Ala+TIMP-2 selectively alters the phosphorylation pattern of VEGFR-2 after VEGF-A stimulation and disrupts the downstream activation of PLC-gamma, Ca(+2) flux, Akt, and eNOS, as well as decreasing cGMP levels. Moreover, we observed an Ala+TIMP-2-induced reduction in cGMP levels typically elevated by exogenous NO donors implicating Ala+TIMP-2 in the direct activation of an isobutylmethylxanthine (IBMX)-sensitive cGMP phosphodiesterase activity. TIMP-2 suppression of endothelial mitogenesis and angiogenesis involves at least two mechanisms, one mediated by protein tyrosine phosphatase inhibition of VEGFR-2 activation as well as downstream signaling and a second mechanism involving direct activation of an IBMX-sensitive phosphodiesterase activity.

Citing Articles

TIMP2 ameliorates blood-brain barrier disruption in traumatic brain injury by inhibiting Src-dependent VE-cadherin internalization.

Tang J, Kang Y, Zhou Y, Shang N, Li X, Wang H J Clin Invest. 2023; 134(3).

PMID: 38015626 PMC: 10849766. DOI: 10.1172/JCI164199.

Knock down of TIMP-2 by siRNA and CRISPR/Cas9 mediates diverse cellular reprogramming of metastasis and chemosensitivity in ovarian cancer.

Escalona R, Chu S, Kadife E, Kelly J, Kannourakis G, Findlay J Cancer Cell Int. 2022; 22(1):422.

PMID: 36585738 PMC: 9805260. DOI: 10.1186/s12935-022-02838-x.

Brevilin A Inhibits VEGF-Induced Angiogenesis through ROS-Dependent Mitochondrial Dysfunction.

Wei B, Hao Z, Zheng H, Qin Y, Zhao F, Shi L Oxid Med Cell Longev. 2022; 2022:5888636.

PMID: 36567856 PMC: 9771652. DOI: 10.1155/2022/5888636.

Effects of Polymorphisms on Retinopathy of Prematurity Risk, Severity, Recurrence, and Treatment Response.

Wu P, Ling X, Kang E, Chen K, Wang N, Liu L Int J Mol Sci. 2022; 23(22).

PMID: 36430677 PMC: 9694036. DOI: 10.3390/ijms232214199.

Breast Cancer Treatment Decreases Serum Levels of TGF-β1, VEGFR2, and TIMP-2 Compared to Healthy Volunteers: Significance for Therapeutic Outcomes?.

Krasnikova V, Pospelova M, Fionik O, Alekseeva T, Samochernykh K, Ivanova N Pathophysiology. 2022; 29(3):537-554.

PMID: 36136069 PMC: 9500649. DOI: 10.3390/pathophysiology29030042.

References

Bhattacharya R, Kwon J, Wang E, Mukherjee P, Mukhopadhyay D . Src homology 2 (SH2) domain containing protein tyrosine phosphatase-1 (SHP-1) dephosphorylates VEGF Receptor-2 and attenuates endothelial DNA synthesis, but not migration*. J Mol Signal. 2008; 3:8. PMC: 2292718. DOI: 10.1186/1750-2187-3-8. View

Bergers G, Brekken R, McMahon G, Vu T, Itoh T, Tamaki K . Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol. 2000; 2(10):737-44. PMC: 2852586. DOI: 10.1038/35036374. View

Seo D, Kim S, Eom S, Yoon H, Cho Y, Kim P . TIMP-2 disrupts FGF-2-induced downstream signaling pathways. Microvasc Res. 2008; 76(3):145-51. PMC: 2574962. DOI: 10.1016/j.mvr.2008.07.003. View

Olsson A, Dimberg A, Kreuger J, Claesson-Welsh L . VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol. 2006; 7(5):359-71. DOI: 10.1038/nrm1911. View

Hanahan D, Folkman J . Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996; 86(3):353-64. DOI: 10.1016/s0092-8674(00)80108-7. View

Wingfield P, Sax J, Stahl S, Kaufman J, Palmer I, Chung V . Biophysical and functional characterization of full-length, recombinant human tissue inhibitor of metalloproteinases-2 (TIMP-2) produced in Escherichia coli. Comparison of wild type and amino-terminal alanine appended variant with implications for.... J Biol Chem. 1999; 274(30):21362-8. DOI: 10.1074/jbc.274.30.21362. View

Seo D, Li H, Qu C, Oh J, Kim Y, Diaz T . Shp-1 mediates the antiproliferative activity of tissue inhibitor of metalloproteinase-2 in human microvascular endothelial cells. J Biol Chem. 2005; 281(6):3711-21. PMC: 1361361. DOI: 10.1074/jbc.M509932200. View

Brew K, Dinakarpandian D, Nagase H . Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta. 2000; 1477(1-2):267-83. DOI: 10.1016/s0167-4838(99)00279-4. View

Saini R, Patel S, Saluja R, Sahasrabuddhe A, Singh M, Habib S . Nitric oxide synthase localization in the rat neutrophils: immunocytochemical, molecular, and biochemical studies. J Leukoc Biol. 2006; 79(3):519-28. DOI: 10.1189/jlb.0605320. View

10.

Stone J, Marletta M . Soluble guanylate cyclase from bovine lung: activation with nitric oxide and carbon monoxide and spectral characterization of the ferrous and ferric states. Biochemistry. 1994; 33(18):5636-40. DOI: 10.1021/bi00184a036. View

11.

Poulin B, Sekiya F, Rhee S . Intramolecular interaction between phosphorylated tyrosine-783 and the C-terminal Src homology 2 domain activates phospholipase C-gamma1. Proc Natl Acad Sci U S A. 2005; 102(12):4276-81. PMC: 555506. DOI: 10.1073/pnas.0409590102. View

12.

Ahmad S, Hewett P, Wang P, Al-Ani B, Cudmore M, Fujisawa T . Direct evidence for endothelial vascular endothelial growth factor receptor-1 function in nitric oxide-mediated angiogenesis. Circ Res. 2006; 99(7):715-22. DOI: 10.1161/01.RES.0000243989.46006.b9. View

13.

Holmqvist K, Cross M, Rolny C, Hagerkvist R, Rahimi N, Matsumoto T . The adaptor protein shb binds to tyrosine 1175 in vascular endothelial growth factor (VEGF) receptor-2 and regulates VEGF-dependent cellular migration. J Biol Chem. 2004; 279(21):22267-75. DOI: 10.1074/jbc.M312729200. View

14.

Dougher M, Terman B . Autophosphorylation of KDR in the kinase domain is required for maximal VEGF-stimulated kinase activity and receptor internalization. Oncogene. 1999; 18(8):1619-27. DOI: 10.1038/sj.onc.1202478. View

15.

Fleming I, Fisslthaler B, Dimmeler S, Kemp B, Busse R . Phosphorylation of Thr(495) regulates Ca(2+)/calmodulin-dependent endothelial nitric oxide synthase activity. Circ Res. 2001; 88(11):E68-75. DOI: 10.1161/hh1101.092677. View

16.

Shultz L, Schweitzer P, Rajan T, Yi T, Ihle J, Matthews R . Mutations at the murine motheaten locus are within the hematopoietic cell protein-tyrosine phosphatase (Hcph) gene. Cell. 1993; 73(7):1445-54. DOI: 10.1016/0092-8674(93)90369-2. View

17.

Guo D, Tan Y, Wang D, Madhusoodanan K, Zheng Y, Maack T . A Rac-cGMP signaling pathway. Cell. 2007; 128(2):341-55. PMC: 1965458. DOI: 10.1016/j.cell.2006.11.048. View

18.

DeFouw L, DeFouw D . Differential phosphodiesterase activity contributes to restrictive endothelial barrier function during angiogenesis. Microvasc Res. 2001; 62(3):263-70. DOI: 10.1006/mvre.2001.2340. View

19.

Fernandez C, Butterfield C, Jackson G, Moses M . Structural and functional uncoupling of the enzymatic and angiogenic inhibitory activities of tissue inhibitor of metalloproteinase-2 (TIMP-2): loop 6 is a novel angiogenesis inhibitor. J Biol Chem. 2003; 278(42):40989-95. DOI: 10.1074/jbc.M306176200. View

20.

Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher A . Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 1999; 399(6736):601-5. DOI: 10.1038/21224. View